Allogene Therapeutics Inc Total Liabilities
Allogene Therapeutics Inc total liabilities. Based on the latest financial reports, Allogene Therapeutics Inc (ALLO) has total liabilities worth $124.44 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Allogene Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Allogene Therapeutics Inc (2017–2024)
Total liabilities of Allogene Therapeutics Inc from 2017 to 2024. This chart illustrates how Allogene Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore ALLO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Allogene Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Allogene Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Caswell Inc
TW:6416
|
Taiwan | NT$1.92 Billion |
|
Lionheart Holdings
NASDAQ:CUB
|
USA | $10.11 Million |
|
Zespol Elektrowni Patnow Adamow Konin SA
WAR:ZEP
|
Poland | zł1.76 Billion |
|
WAWEL SA
WAR:WWL
|
Poland | zł116.87 Million |
|
Clinuvel Pharmaceuticals Ltd
AU:CUV
|
Australia | AU$20.68 Million |
|
INTERGRATED DIA.H DL 025
F:8I8
|
Germany | €3.22 Billion |
|
NEOBO FASTIGHETER
ST:NEOBO
|
Sweden | Skr7.48 Billion |
|
P.C.B Tec
TA:PCBT
|
Israel | ILA76.95 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Allogene Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Allogene Therapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Allogene Therapeutics Inc Total Liabilities Ratios Explained
Allogene Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allogene Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allogene Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Allogene Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $126.53 Million | -3.12% |
| 2023-12-31 | $130.60 Million | -15.57% |
| 2022-12-31 | $154.70 Million | +23.14% |
| 2021-12-31 | $125.63 Million | -15.24% |
| 2020-12-31 | $148.21 Million | +66.94% |
| 2019-12-31 | $88.78 Million | +25.59% |
| 2018-12-31 | $70.69 Million | +3534450.00% |
| 2017-12-31 | $2.00K | -- |
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell a… Read more